948 Results

People

  1. Kris
    Kris
  2. Kelsen
    Kelsen
  3. Motzer
    Motzer
  4. O'Reilly
    O'Reilly
  5. Saltz
    Saltz
  6. Tyson
    Tyson
  7. Gralla
    Gralla
  8. Hudis
    Hudis
  9. Scher
    Scher
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)
  7. Center for Hematologic Malignancies (109)
  8. Genitourinary Oncology Service (106)
  9. Nursing (101)
  10. Surgery (97)
  1. "vomiting"
Formats
  1. Journal Article (896)
  2. Review (27)
  3. Conference Paper (8)
  4. Editorial (6)
  5. Research Letter (4)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Book Section (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)

More Groups

People
  1. Mark Kris (70)
  2. David Kelsen (40)
  3. Robert Motzer (39)
  4. Eileen O'Reilly (30)
  5. Leonard Saltz (30)
  6. Leslie Tyson (28)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (44)
  4. 2022 (32)
  5. 2021 (15)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Cancer (47)
  3. Clinical Cancer Research (44)
  4. Lancet Oncology (38)
  5. Gynecologic Oncology (31)
  6. Cancer Treatment Reports (26)

More Publications

Publishers
  1. Elsevier Inc. (145)
  2. American Society of Clinical Oncology (92)
  3. Elsevier Science, Inc. (74)
  4. Springer (72)
  5. Oxford University Press (64)
  6. Wiley Blackwell (63)

More Publishers

Results (948)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104)
    Journal Article

    Ho, A. L.; Foster, N. R.; Deraje Vasudeva, S.; Katabi, N.; Antonescu, C. R.; Frenette, G. P.; Pfister, D. G.; Erlichman, C.; Schwartz, G. K.
    Cancer (2024)

    Fulltext@MSK | Save
  • Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001
    Journal Article

    Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M.; Wang, M.; Arnason, J.; Purev, E.; Maloney, D. G.; Andreadis, C.; Sehgal, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
    Journal Article

    Patel, S. P.; Alonso-Gordoa, T.; Banerjee, S.; Wang, D.; Naidoo, J.; Standifer, N. E.; Palmer, D. C.; Cheng, L. Y.; Kourtesis, P.; Ascierto, M. L.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
    Journal Article

    Lumish, M.; Chui, M. H.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Cohen, S.; Friedman, C.; Grisham, R.; Konner, J.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
    Journal Article

    Brahmer, J. R.; Long, G. V.; Hamid, O.; Garon, E. B.; Herbst, R. S.; Andre, T.; Armand, P.; Bajorin, D.; Bellmunt, J.; Burtness, B.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors
    Journal Article

    Lewis, K. D.; Peris, K.; Sekulic, A.; Stratigos, A. J.; Dunn, L.; Eroglu, Z.; Chang, A. L. S.; Migden, M. R.; Yoo, S. Y.; Mohan, K.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Oncology for the rhinologist
    Review

    Tam, K.; Dunn, L. A.; Cohen, M. A.
    Current Opinion in Otolaryngology & Head and Neck Surgery (2024)

    Fulltext@MSK | Save
  • First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
    Journal Article

    Janku, F.; Kim, T. M.; Iyer, G.; Spreafico, A.; Elez, E.; de Jonge, M.; Yamamoto, N.; van der Wekken, A. J.; Ascierto, P. A.; Maur, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • The medial transorbital approach in cranioendoscopic skull base tumor resections for locally advanced tumors
    Journal Article

    Scholfield, D. W.; Levyn, H.; Tabar, V. S.; Ganly, I.; Della Rocca, D.; Cohen, M. A.
    Journal of Clinical Neuroscience (2023)

    Fulltext@MSK | Save
  • Use of tamibarotene, a potent and selective RARĪ± agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression
    Journal Article

    Stein, E. M.; de Botton, S.; Cluzeau, T.; Pigneux, A.; Liesveld, J. L.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Braun, T.; Roboz, G. J.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save